KDR and breast cancer: VEGF-A inhibition using bevacizumab failed to inhibit VM in breast cancer cells in vitro, furthermore, sunitinib, a multi targeting anti-VEGFR inhibitor, even promoted VM in breast cancer mouse models (Dey et al., 2015; Sun et al., 2017).